Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study

PE cfDNA genotyping has clinical applicability for NSCLC patients and can serve as an additional source for molecular testing. Incorporating PE NGS cfDNA analysis into genetic testing enhances diagnostic yield and aids in identifying actionable mutations in clinical practice.